Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.77 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.77 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.77 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | SRC | P12931 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.77 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.77 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.72 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.72 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.72 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.72 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.66 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.66 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.66 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389326 | 0.99 | P2RY1 (0.75) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL22099721 | 0.93 | P2RY1 (0.69) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL985843 | 0.93 | P2RY1 (0.71) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Phosphate SCHEMBL2828289 | 0.92 | P2RY1 (0.76) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL32662848 | 0.92 | RNASEL (0.68) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Triphosphate SCHEMBL27776323 | 0.92 | P2RY1 (0.73) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL22498771 | 0.91 | P2RY1 (0.72) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL30751027 | 0.91 | P2RY1 (0.72) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine Diphosphate SCHEMBL424711 | 0.91 | P2RY1 (0.72) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| Adenosine SCHEMBL21067523 | 0.91 | P2RY2 (0.62) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 855 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291664-B1 | SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY | UNIV NORTH CAROLINA STATE (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026090321-A1 | TREATMENT OF CANCER WITH A KRAS INHIBITOR | ALTEROME THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260097020-A1 | THERAPEUTIC USE OF AROMATASE INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS FOR THE TREATMENT OF MALIGNANCIES | UNIV CINCINNATI (US) | 2026-04-09 | — | — | US | claimed |
| EP-4719372-A1 | 5-FU COMBINATIONS FOR USE IN TREATING ACTINIC KERATOSIS OR BASAL CELL CARCINOMA | Alexandroff, Anton (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719373-A1 | PHOTODYNAMIC THERAPY COMBINATIONS FOR IMPROVEMENT OF ACTINIC KERATOSIS, ACNE AND BASAL CELL CARCINOMA | Alexandroff, Anton (GB) | 2026-04-08 | — | — | EP | claimed |
| US-12564589-B2 | Methods for treating cancer, reducing side effects of cancer treatment, and preventing the recurrence of cancer | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-03-03 | — | — | US | claimed |
| WO-2025245463-A9 | COMBINATION THERAPIES | MERCK PATENT GMBH (DE) | 2025-12-26 | — | — | WO | claimed |
| WO-2025264823-A1 | TREATMENT OF DISEASE | METASHAPE PHARMA AG (CH) | 2025-12-26 | — | — | WO | claimed |
| WO-2025245463-A1 | COMBINATION THERAPIES | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| CN-115980169-A | Use of mass spectrometry techniques for identifying muscle biomarkers | 中国科学院动物研究所 | 2023-04-18 | — | — | CN | claimed |
| CN-114042160-B | CTD-2256P15.2 and application of encoded micro-peptide thereof as target in development of tumor treatment drugs | 中国科学院动物研究所 | 2023-04-14 | — | — | CN | claimed |
| WO-2022245922-A1 | POLY-ADP RIBOSE (PAR) TRACKER OPTIMIZED SPLIT-PROTEIN REASSEMBLY PAR DETECTION REAGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| WO-2022225995-A1 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | claimed |
| US-11480568-B2 | Diagnosis of autoimmune diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-10-25 | — | — | US | claimed |
| US-11459597-B2 | Methods for the design of mechanism-based sirtuin activating compounds | CHAKRABARTI ADVANCED TECHNOLOGY LLC (US) | 2022-10-04 | — | — | US | claimed |
| WO-2022174144-A1 | SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY | NORTH CAROLINA STATE UNIVERSITY (US) | 2022-08-18 | — | — | WO | claimed |
| US-20220072167-A1 | Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates | ACTINIUM PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | claimed |
| WO-2022020359-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIGH GRADE SUBTYPES OF UTERINE CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564589-B2 | Methods for treating cancer, reducing side effects of cancer treatment, and preventing the recurrence of cancer | BRCA1, PARP1, PARP2 | P2RY1 1722/4885P2RY2 1433/4885P2RX1 2256/4885 |
| US-20260097020-A1 | THERAPEUTIC USE OF AROMATASE INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS FOR THE TREATMENT OF MALIGNANCIES | PARP2, PARP12, PARP1 | P2RY1 306/4885P2RY2 138/4885P2RX1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.